- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05963074
Une étude visant à personnaliser les schémas thérapeutiques de traitement à l'ibrutinib pour les participants atteints de leucémie lymphoïde chronique non traitée auparavant (TAILOR)
Étude multicohorte pour personnaliser les schémas thérapeutiques de traitement par l'ibrutinib pour les patients atteints de leucémie lymphoïde chronique non traitée auparavant
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- QEII Health Sciences Centre
-
-
Ontario
-
St. Catharines, Ontario, Canada, L2S 0A9
- Niagara Health System
-
-
-
-
-
Barcelona, Espagne, 08035
- Hosp Univ Vall D Hebron
-
Córdoba, Espagne, 14004
- Hosp Reina Sofia
-
Madrid, Espagne, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Espagne, 28034
- Hosp. Univ. Ramon Y Cajal
-
Santander, Espagne, 39008
- Hosp. Univ. Marques de Valdecilla
-
Santiago de Compostela, Espagne, 15706
- Hosp. Clinico Univ. de Santiago
-
-
-
-
-
Clermont-Ferrand, France, 63100
- CHU de Clermont Ferrand
-
Nantes, France, 44000
- CHU Nantes
-
Paris, France, 75651
- Hopital Pitie Salpetriere
-
Pierre-Bénite, France, 69495
- CHU Lyon Sud
-
Reims, France, 51100
- CHU de Reims
-
Strasbourg, France, 67200
- Institut de Cancerologie Strasbourg Europe ICANS
-
-
-
-
-
Budapest, Hongrie, 1088
- Semmelweis Egyetem
-
Győr, Hongrie, 9024
- Gyor Moson Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz
-
Nyíregyháza, Hongrie, 4400
- Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz
-
Szeged, Hongrie, 6725
- University of Szeged
-
-
-
-
-
Bari, Italie, 70124
- U.O. Ematologia Istituto Tumori Giovanni Paolo II
-
Ferrara, Italie, 44124
- Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant Anna
-
Florence, Italie, 50134
- Azienda Ospedaliero Universitaria Careggi
-
Milan, Italie, 20132
- Ospedale San Raffaele
-
Milan, Italie, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Novara, Italie, 28100
- Ospedale Maggiore della Carita
-
Padova, Italie, 35129
- Universita degli Studi di Padova Azienda Ospedaliera di Pa
-
Palermo, Italie, 90146
- Ospedale Villa Sofia-Cervello
-
Perugia, Italie, 06132
- Azienda Ospedaliera di Perugia Ospedale S.Maria della Misericordia
-
Roma, Italie, 00161
- Umberto I Policlinico di Roma
-
Roma, Italie, 00136
- Ematologia Fondazione Univ. Policlinico Gemelli Università Cattolica del Sacro Cuore
-
-
-
-
-
Biała Podlaska, Pologne, 21 500
- Wojewodzki Szpital Specjalistyczny
-
Brzozów, Pologne, 36 200
- Szpital Specjalistyczny w Brzozowie
-
Gdynia, Pologne, 81-519
- Szpitale Pomorskie Sp z o o
-
Kielce, Pologne, 25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Krakow, Pologne, 30 688
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
-
Lodz, Pologne, 93 513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im M Kopernika w Lodzi
-
Lublin, Pologne, 20 090
- Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
-
-
-
-
-
Brno-Bohunice, Tchéquie, 625 00
- Fakultni nemocnice Brno
-
Hradec Králové, Tchéquie, 500 05
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Tchéquie, 779 00
- Fakultni nemocnice Olomouc
-
Ostrava - Poruba, Tchéquie, 708 52
- Fakultni Nemocnice Ostrava
-
Prague, Tchéquie, 100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Prague, Tchéquie, 128 00
- Ustav Hematologie A Krevni Transfuze
-
-
-
-
California
-
Cerritos, California, États-Unis, 90703
- The Oncology Institute Clinical Research
-
Los Alamitos, California, États-Unis, 90720
- Cancer and Blood Specialty Clinic
-
San Luis Obispo, California, États-Unis, 93401
- SLO Oncology and Hematology Health Center
-
Santa Rosa, California, États-Unis, 95403
- Providence Medical Foundation
-
Whittier, California, États-Unis, 90602
- PIH Health Hospital
-
-
Colorado
-
Grand Junction, Colorado, États-Unis, 81505
- Grand Valley Oncology
-
-
Florida
-
Miami Beach, Florida, États-Unis, 33140-2948
- Mount Sinai Medical Center Campus
-
North Miami Beach, Florida, États-Unis, 33169
- The Oncology Institute
-
Orange, Florida, États-Unis, 32763
- Mid Florida Hematology Oncology
-
-
Idaho
-
Boise, Idaho, États-Unis, 83702
- Boise VA Medical Center
-
-
Illinois
-
Hinsdale, Illinois, États-Unis, 60521
- Hope and Healing Cancer Services
-
Springfield, Illinois, États-Unis, 62702
- Springfield Clinic
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52246
- Iowa City VA Health Care System
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55404
- Minnesota Oncology Hematology P A
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64132
- Research Medical Center
-
-
New Jersey
-
Flemington, New Jersey, États-Unis, 08822
- Hunterdon Hematology Oncology
-
Florham Park, New Jersey, États-Unis, 07932
- Summit Medical Group
-
-
New York
-
Nyack, New York, États-Unis, 10960
- Hematology Oncology Associates of Rockland
-
-
North Carolina
-
Goldsboro, North Carolina, États-Unis, 27534
- Southeastern Medical Oncology Center
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45242
- Oncology Hematology Care
-
-
Oregon
-
Eugene, Oregon, États-Unis, 97401
- Willamette Valley Cancer Institute and Research Center
-
Portland, Oregon, États-Unis, 97239
- OHSU Knight Cancer Institute
-
-
Texas
-
El Paso, Texas, États-Unis, 79915
- Renovatio Clinical
-
Fort Worth, Texas, États-Unis, 76104
- Texas Oncology-Fort Worth Cancer Center
-
Houston, Texas, États-Unis, 77030
- The University of Texas MD Anderson Cancer Center
-
The Woodlands, Texas, États-Unis, 77380
- Renovatio Clinical 1
-
The Woodlands, Texas, États-Unis, 77380
- Texas Oncology-Gulf Coast
-
-
Utah
-
Ogden, Utah, États-Unis, 84405
- Community Cancer Trials of Utah
-
-
Virginia
-
Manassas, Virginia, États-Unis, 20110
- Virginia Cancer Specialists
-
Virginia Beach, Virginia, États-Unis, 23456
- Virginia Oncology Associates
-
-
Washington
-
Seattle, Washington, États-Unis, 98108
- VA Puget Sound Healthcare System
-
Vancouver, Washington, États-Unis, 98684
- Northwest Cancer Specialists PC
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Diagnosis of chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) as per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 diagnostic criteria
- For ibruinib + venetocIax (I+V) cohorts: eastern cooperative oncology group (ECOG) performance status of 0-1. For ibrutinib monotherapy cohorts: ECOG performance status of 0-2
- Measurable nodal disease by computed tomography (CT), defined as at least 1 lymph node greater than and equal to (>=) 1.5 centimeters (cm) in longest diameter
- A participant using oral contraceptives must use an additional contraceptive method
- A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or until 1 month after last dose or per local label if more conservative (for example, 3 months in European Union or Canada and 1 month in United States)
Exclusion Criteria:
- Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura, such as those participants with a declining hemoglobin level or platelet count secondary to autoimmune destruction within the 4 weeks prior to first dose of study treatment, or the need for prednisone greater than (>) 20 milligrams (mg) daily (or corticosteroid equivalent) to treat or control the autoimmune disease
- Known bleeding disorders (example, von Willebrand's disease or hemophilia)
- Stroke or intracranial hemorrhage within 6 months prior to enrollment
- Known or suspected Richter's transformation or central nervous system (CNS) involvement
- Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class II, III, or IV congestive heart failure as defined by the New York Heart Association Functional Classification
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cohort 1a: Ibrutinib Lead-in+Fixed Duration Ibrutinib+Venetoclax
Participants will receive ibrutinib 420 milligrams (mg) capsule every day (QD) for a lead-in of 3 cycles (1 cycle = 28 days). From Cycle 4, venetoclax 400 mg tablet dose ramp-up (from 20 to 400 mg over 5 weeks) will begin, and venetoclax 400 mg QD will be administered with ibrutinib 420 mg QD, orally for 12 cycles through Cycle 15. |
Ibrutinib capsules will be administered orally.
Autres noms:
Venetoclax tablets will be administered orally.
Autres noms:
|
|
Expérimental: Cohort 1b: Ibrutinib Lead-in+Fixed Duration Ibrutinib+Venetoclax
Participants will receive ibrutinib 420 mg capsule QD for a lead-in of 3 cycles (1 cycle = 28 days). From Cycle 4, venetoclax 400 mg tablet dose ramp-up (from 20 to 400 mg over 5 weeks) will begin and ibrutinib dose will be reduced to 280 mg and will be administered QD, venetoclax 400 mg tablets QD will be administered with ibrutinib 280 mg for 12 cycles through Cycle 15. |
Ibrutinib capsules will be administered orally.
Autres noms:
Venetoclax tablets will be administered orally.
Autres noms:
|
|
Expérimental: Cohort 2a: Continuous Ibrutinib Monotherapy
Participants will receive ibrutinib 420 mg QD (or last tolerated dose) until disease progression (PD) or unacceptable toxicity. |
Ibrutinib capsules will be administered orally.
Autres noms:
|
|
Expérimental: Cohort 2b: Continuous Ibrutinib Monotherapy
Participants will receive ibrutinib 420 mg QD for 1 cycle (1 cycle = 28 days) followed by Ibrutinib 280 mg QD (or last tolerated dose) and continue until disease progression or unacceptable toxicity. |
Ibrutinib capsules will be administered orally.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Best Overall Response Rate (ORR)
Délai: Up to 5 years
|
Best ORR is defined as the percentage of participants who achieve complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria as assessed by investigator. |
Up to 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Complete Response (CR) Rate
Délai: Up to 5 years
|
CR rate is defined as the percentage of participants achieving a best overall response of CR or CRi per iwCLL 2018 criteria as assessed by investigator. |
Up to 5 years
|
|
Duration of Response (DOR)
Délai: Up to 5 years
|
DOR is defined as the duration in days from the date of initial documentation of PR or better to the date of first documented evidence of PD or death. |
Up to 5 years
|
|
Progression Free Survival (PFS)
Délai: Up to 5 years
|
PFS by investigator assessment is defined as the duration from date of randomization to date of PD or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Overall Survival (OS)
Délai: Up to 5 years
|
OS is defined as the time from date of randomization to date of death from any cause. |
Up to 5 years
|
|
Cohorts 1a and 1b: Minimal Residual Disease (MRD) Negative Rate
Délai: Up to 5 years
|
MRD-negative rate is defined as the percentage of participants who reach MRD-negative status (that is, less than [<] 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes or <0.01 percentage [%]) in the peripheral blood. |
Up to 5 years
|
|
Number of Participants with Adverse Events (AEs)
Délai: Up to 5 years
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 5 years
|
|
Number of Participants with AEs by Severity
Délai: Up to 5 years
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 5 years
|
|
Percentage of Participants with Rate of Discontinuation due to AEs
Délai: Up to 5 years
|
Percentage of participants with rate of discontinuation due to AEs will be reported. |
Up to 5 years
|
|
Percentage of Participants with Dose Reduction due AEs
Délai: Up to 5 years
|
Percentage of participants with dose reduction due AEs will be reported. |
Up to 5 years
|
|
Adherence Rates
Délai: Up to 5 years
|
The adherence rate is defined as the percentage of total dose taken over the total dose prescribed. |
Up to 5 years
|
|
Duration of Treatment
Délai: Up to 5 years
|
Duration of treatment is defined as the time period in days between the date of first study treatment administration and date of last administration. |
Up to 5 years
|
|
Time to Worsening as Measured by EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L)
Délai: Up to 5 years
|
Time to worsening is defined as time interval (months) from randomization to first observation of deterioration. Time to worsening as measured by EQ-5D-5L will be reported. |
Up to 5 years
|
|
Time to Worsening as Measured by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ)-C30)
Délai: Up to 5 years
|
Time to worsening is defined as time interval from randomization to first observation of deterioration. Time to worsening as measured by EORTC QLQ-C30 will be reported. |
Up to 5 years
|
|
Time to Worsening as Measured by EORTC QLQ-CLL17
Délai: Up to 5 years
|
Time to worsening is defined as time interval from randomization to first observation of deterioration. Time to worsening as measured by EORTC QLQ-CLL17 will be reported. |
Up to 5 years
|
|
Time to Worsening as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score
Délai: Up to 5 years
|
Time to Worsening is defined as time interval (months) from randomization to first observation of deterioration. Time to worsening as measured by FACIT-fatigue total score will be reported. |
Up to 5 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Maladie chronique
- Attributs de la maladie
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Leucémie, cellule B
- Leucémie, Lymphoïde
- Leucémie
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Leucémie lymphocytaire chronique à cellules B
- vénitoclax
- ibrutinib
Autres numéros d'identification d'étude
- 54179060CLL2032
- 54179060CLL2032 (Autre identifiant: Janssen Research & Development, LLC)
- 2023-504044-34-00 (Identificateur de registre: EUCT number)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .